相关实验视频

Updated: Sep 13, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

在妇科癌症中抗体-药物结合物:当前的情况,临床数据和新兴的点

Jinhui He¹, Mi Chen², Li Jia²

¹Affiliated Hospital of Chengdu University, Chengdu Seventh People's Hospital, Department of Obstetrics and Gynecology, Chengdu, China.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

|July 31, 2025

概括

抗体-药物合物 (ADC) 为妇科恶性瘤提供有针对性的癌症治疗. 虽然已批准的ADC有希望,但毒性和耐药性等挑战需要进一步研究,以改善精确治疗.

科学领域:

妇科瘤学妇科瘤学
药理学药理学是指药理学的学科.
免疫治疗是一种免疫疗法.

背景情况:

抗体-药物合物 (ADCs) 在向癌症治疗方面取得了重大进展.
ADCs将单克隆抗体与强大的细胞毒剂相结合,用于精确的药物输送.
它们通过向瘤特异性抗原,显示出在治疗妇科恶性瘤方面的巨大潜力.

研究的目的:

审查目前的临床应用和ADC在妇科癌症的研究进展.
总结关键的临床试验,有效性,安全性和与ADC治疗相关的挑战.
讨论在妇科瘤学中优化基于ADC的治疗方法的未来策略.

主要方法:

综合审查目前的临床应用和ADC在妇科癌症的研究进展.
分析关键的临床试验,治疗疗效和安全性.
讨论ADC治疗的挑战和未来优化策略.

主要成果:

两种FDA批准的ADCs,mirvetuximab soravtansine和tisotumab vedotin,分别在卵巢和宫癌中表现出疗效.
针对各种抗原的研究ADC在正在进行的试验中显示了初步的有效性.
挑战包括眼睛和肺部毒性,神经病变,抗原异质性和耐药性.

结论:

ADCs是妇科恶性瘤的有前途的治疗类别,经批准的药物显示出显著的响应率.
正在进行的新型ADC和组合疗法的研究和开发正在扩大治疗选择.
解决毒性和耐药性等挑战对于在妇科瘤学中推进基于ADC的精密医学至关重要.

关键词:

抗体与药物联合体 (ADCs) 是一种抗体与药物联合体.宫癌宫癌是什么妇科恶性瘤妇科恶性瘤卵巢癌卵巢癌卵巢癌有针对性的治疗.

更多相关视频

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Conjugated Proteins

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...